Medicare Negotiation Round Two Will Be Dominated By Oral Cancer Drugs, Researchers Predict

 
• By Cathy Kelly
  
Generate a summary of this article
Listen to this article
Beta

A number of diabetes drugs are also expected to be targeted in the next cycle of the price negotiation program, led by Novo Nordisk’s Ozempic.

Round 2
Focus On Cancer Agents May Fuel Opposition To Timeline For Small Molecule Drugs • Source: Shutterstock

Cancer will replace diabetes/heart disease as the dominant disease category in the upcoming list of Part D drugs selected for the Medicare price negotiation process, researchers Sean Sullivan and Emma Cousin from the University of Washington and Inmaculada Hernandez of the University of California San Diego predict in a new analysis.

Key Takeaways

  • As many as six oral cancer drugs could be selected for Medicare price negotiation in the next round, which begins in 2025 for prices going into effect in 2027, according to a new analysis by researchers at the University of Washington and the University of California San Diego.

Using the selection criteria laid out in the Inflation Reduction Act, the researchers produced a list of 13 drugs they...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Medicare

CMS Should ‘Clarify’ That Part B Inflation Rebates Do Not Apply In Medicare Advantage, Pharma Urges

The Centers for Medicare and Medicaid Services is considering imposing price inflation rebates on Part B drugs furnished to enrollees in Medicare Advantage plans in addition to those covered by fee-for-service Medicare.

PS-MarketAccess (Premium-2): Why Financial Scammers Are So Successful Targeting Doctors

 
• By Nabil

Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.

PBM Legislation: Medicare Rebate Reform May Be Challenging Amid Disruption From Redesign

 
• By Cathy Kelly

US lawmakers will undoubtedly continue to work on pharmacy benefit manager reform legislation in 2025, given its bipartisan support. But policies impacting rebates that could lead to higher premiums in Part D may be a tough sell in the midst of the benefit redesign.

Accelerated Approvals In Medicare: CED Guidance Notes Ongoing Concern With Surrogate Endpoints

 
• By Cathy Kelly

Medicare coverage with evidence development final guidance includes few substantive changes from the proposed version despite biopharma stakeholder concerns.

More from Government Payers

PBMs and Vertical Integration: CBO Adds To Growing Concerns About Negative Impacts

 
• By Sarah Karlin-Smith

Congressional Budget Office responses to questions from US lawmakers on pharmacy benefit managers could add to the momentum for PBM reforms to go further than the current leading proposals.

Pink Sheet Podcast: What We Learned From The First Batch Of Medicare Negotiated Drug Prices

 
• By Derrick Gingery, Sarah Karlin-Smith, and Cathy Kelly

Pink Sheet reporter and editors discuss the take-aways from the landmark first Medicare negotiated drug prices and what additional information remains outstanding.

A Better Deal: Medicare Discounts Surpass Estimated PBM-Negotiated Rebates

 
• By Cathy Kelly

But the amount of savings realized when the Medicare negotiated prices go into effect in 2026 remains the subject of debate.